TG Therapeutics Inc TGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
-
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
-
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
-
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
-
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
-
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
-
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases
-
AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move
Trading Information
- Previous Close Price
- $23.33
- Day Range
- $23.35–24.02
- 52-Week Range
- $6.46–26.41
- Bid/Ask
- $23.50 / $23.88
- Market Cap
- $3.69 Bil
- Volume/Avg
- 1.8 Mil / 3.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- 39.71
- Price/Sales
- 10.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 264
- Website
- https://www.tgtherapeutics.com
Comparables
Valuation
|
Metric
|
TGTX
|
EXEL
|
VERA
|
|---|---|---|---|
Price/Earnings (Normalized) | 39.71 | 17.02 | — |
Price/Book Value | 20.78 | 3.49 | 7.26 |
Price/Sales | 10.36 | 3.97 | — |
Price/Cash Flow | 27.07 | 16.25 | — |
Price/Earnings
TGTX
EXEL
VERA
Financial Strength
|
Metric
|
TGTX
|
EXEL
|
VERA
|
|---|---|---|---|
Quick Ratio | 2.77 | 4.05 | 20.98 |
Current Ratio | 3.58 | 4.27 | 21.43 |
Interest Coverage | 8.72 | — | −19.84 |
Quick Ratio
TGTX
EXEL
VERA
Profitability
|
Metric
|
TGTX
|
EXEL
|
VERA
|
|---|---|---|---|
Return on Assets (Normalized) | 40.17% | 14.82% | −35.17% |
Return on Equity (Normalized) | 94.57% | 19.05% | −45.77% |
Return on Invested Capital (Normalized) | 57.84% | 14.99% | −40.21% |
Return on Assets
TGTX
EXEL
VERA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kwvrjsmg | Xyyr | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tsmxmvb | Zyzbp | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bxttxzvnw | Fqctszf | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pqdhqvmc | Jwbtg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gxwnlvsls | Byzt | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bhygcch | Qjdg | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ltpxkdzbb | Phx | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qwchxhvj | Fnrcv | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lhlsgrjgk | Tnmlmh | $13.4 Bil | |||
| Incyte Corp
INCY
| Byjyvdkpl | Bcskw | $12.7 Bil |
United States